Skip to main content


We're creating a new version of this page. See preview

  • Poster presentation
  • Open Access

Dopamine and GABA outflow at different glucose concentrations is mediated by ATP-sensitive potassium channels in the rat caudate nucleus

  • 1,
  • 1,
  • 1 and
  • 1
BMC Neuroscience20078 (Suppl 1) :P6

  • Published:


  • Sulfonyl Urea
  • Glibenclamide
  • Gaba Concentration
  • Inhibitory GABAergic
  • Extracellular Glucose

ATP-sensitive potassium (K(ATP)) channels have been identified to play an important role in the release of neurotransmitters. In the caudate nucleus, dopaminergic afferences from the substantia nigra are known to be modulated by GABA via presynaptic inhibitory GABA(A) receptors. The aim of this study was to investigate the impact of K(ATP) channels on dopamine (DA) and GABA outflow at different glucose concentrations. Therefore, slices of the rat caudate nucleus were incubated in superfusion chambers and DA and GABA concentrations were measured by HPLC. It was shown that after glucose reduction from 10 to 7 mM, DA outflow increased from 11.2 ± 0.8 to 14.1 ± 1.3 nM, while GABA concentrations decreased from 6.7 ± 2.0 to 3.2 ± 1.6 nM. When the K(ATP) channel blocker glibenclamide (10 μM) was added to glucose 7 mM, modulations of both DA and GABA outflow were abolished. We could demonstrate that reduction of extracellular glucose generates desinhibition of DAergic outflow due to decreased GABAergic activity in a neuronal network of the rat caudate nucleus. The glucose effects were mediated by K(ATP) channels, as they were completely antagonized by the K(ATP) channel blocker and sulfonyl urea receptor agonist glibenclamide. Further, since glucose reduction to 7 mM decreased GABA but not DA outflow, we suggest different types of K(ATP) channels with low ATP affinity on inhibitory GABAergic and high affinity on excitatory DAergic neurons.

Authors’ Affiliations

University of Luebeck, Luebeck, Germany


© Kolbe et al; licensee BioMed Central Ltd. 2007

This article is published under license to BioMed Central Ltd.